



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board

2:00pm

Thursday, August 10, 2017
DMAS Board Room 13th Floor

Agenda

1. **Call to Order and Introductions** – Randy Ferrance, MD, Chair
2. **Minutes**
 - a. Approval of Minutes from May 11, 2017 meeting
3. **New Drugs**
 - a. Alunbrig™ (brigatinib)
 - b. Austedo™ (deutetrabenazine)
 - c. Ingrezza™ (valbenazine)
 - d. Kisqali-Femara Co-Pak® (ribociclib-letrozole)
 - e. Kovanaze™ (tetracaine HCl and oxymetazoline)
 - f. Rydapt® (midostaurin)
 - g. Selzentry® (maraviroc)
 - h. Xadago (safinamide)
 - i. Zejula™ (niraparib)
 - j. New drugs: PDL-eligible; physician-administered injectables
4. **Service Authorizations**
5. **Topics for Discussion**
 - a. Acute Dosing of Proton Pump Inhibitors
 - b. Gender Edit for Point of Sale System
 - c. Pediatric and Adult Opioid Utilization
 - k. Naloxone Utilization Review
 - l. Analysis of Compounded Medications
 - m. Synagis Utilization
 - n. DUR Quarterly Newsletter
6. **Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
 - d. Top Diagnoses by Age
 - e. AAP Report
7. **Adjournment**